JP2022513176A5 - - Google Patents

Info

Publication number
JP2022513176A5
JP2022513176A5 JP2021531335A JP2021531335A JP2022513176A5 JP 2022513176 A5 JP2022513176 A5 JP 2022513176A5 JP 2021531335 A JP2021531335 A JP 2021531335A JP 2021531335 A JP2021531335 A JP 2021531335A JP 2022513176 A5 JP2022513176 A5 JP 2022513176A5
Authority
JP
Japan
Prior art keywords
peptide analog
peg
approximately
oxm
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513176A (ja
JP7798569B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/083022 external-priority patent/WO2020109526A2/en
Publication of JP2022513176A publication Critical patent/JP2022513176A/ja
Publication of JP2022513176A5 publication Critical patent/JP2022513176A5/ja
Application granted granted Critical
Publication of JP7798569B2 publication Critical patent/JP7798569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531335A 2018-11-30 2019-11-29 オキシントモジュリンペプチド類似体製剤 Active JP7798569B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773651P 2018-11-30 2018-11-30
US62/773,651 2018-11-30
US201962821382P 2019-03-20 2019-03-20
US62/821,382 2019-03-20
PCT/EP2019/083022 WO2020109526A2 (en) 2018-11-30 2019-11-29 Oxyntomodulin peptide analog formulations

Publications (3)

Publication Number Publication Date
JP2022513176A JP2022513176A (ja) 2022-02-07
JP2022513176A5 true JP2022513176A5 (https=) 2024-06-27
JP7798569B2 JP7798569B2 (ja) 2026-01-14

Family

ID=68886992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531335A Active JP7798569B2 (ja) 2018-11-30 2019-11-29 オキシントモジュリンペプチド類似体製剤

Country Status (11)

Country Link
US (1) US12441776B2 (https=)
EP (1) EP3886807A2 (https=)
JP (1) JP7798569B2 (https=)
KR (1) KR20210135476A (https=)
CN (2) CN120514662A (https=)
AU (1) AU2019387342B2 (https=)
CA (2) CA3120794C (https=)
IL (1) IL283553A (https=)
MX (2) MX2021006259A (https=)
PH (1) PH12021551243A1 (https=)
WO (1) WO2020109526A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140061A (zh) * 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
CA3194447A1 (en) * 2020-11-09 2022-05-12 Neel K. Krishna Peptide formulations and methods of use
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CA3201539A1 (en) * 2020-12-07 2022-06-16 Vyjayanthi Krishnan Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
WO1989010756A1 (fr) 1988-05-06 1989-11-16 Toray Industries, Inc. COMPOSITION D'INTERFERON beta STABLE
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5858975A (en) 1994-11-07 1999-01-12 Kyowa Hakko Kogyo Co., Ltd. Oxyntomodulin peptide having cardiotonic activity and insulin release-bromating activity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69624488T2 (de) 1995-08-10 2003-06-26 Kazunori Kataoka Blockcopolymere mit funktionellen gruppen an beiden kettenenden
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DE69939036D1 (de) 1998-04-28 2008-08-14 Serono Lab PEG Konjugate von LHRH Analogen
US6617276B1 (en) 2000-07-21 2003-09-09 Johnson Matthey Public Limited Company Hydrocarbon trap/catalyst for reducing cold-start emissions from internal combustion engines
IL139400A0 (en) 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
KR100870013B1 (ko) 2002-08-27 2008-11-21 삼성전자주식회사 박막 트랜지스터 어레이 기판 및 그 제조 방법
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
AU2007267798A1 (en) 2006-05-26 2007-12-06 Ipsen Pharma S.A.S. Methods for site-specific pegylation
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN102281865B (zh) 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
MX2011009803A (es) 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
US9301938B2 (en) 2009-09-23 2016-04-05 Biokier, Inc. Composition and method for treatment of diabetes
US8415926B2 (en) 2009-10-19 2013-04-09 Apple Inc. In-situ battery health detector and end-of-life indicator
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
WO2012101619A1 (en) 2011-01-24 2012-08-02 Ben Gurion University Of The Negev Research And Development Authority A method for evaluating a mental disorder
KR102092206B1 (ko) * 2011-06-02 2020-03-24 옵코 바이오로직스 리미티드 장기-작용성 glp-1/글루카곤 수용체 작용제
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
US20150111246A1 (en) 2012-04-24 2015-04-23 Astrazeneca Pharmaceuticals Lp Site-specific enzymatic modification of exendins and analogs thereof
EA201492269A1 (ru) 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (en) * 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
MX387560B (es) 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
CN104926934B (zh) 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
EP3230309B1 (en) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
EP3468610A1 (en) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same

Similar Documents

Publication Publication Date Title
JP2022513176A5 (https=)
KR101284202B1 (ko) 아고멜라틴 할로겐산염 복합체 및 이의 제조 방법
JP2021505614A5 (https=)
CN102190594A (zh) 阿戈美拉汀氯化氢水合物及其制备方法
Schade et al. Zanamivir amidoxime-and N-hydroxyguanidine-based prodrug approaches to tackle poor oral bioavailability
JPS6121938B2 (https=)
CN114040906B (zh) 帕拉米韦三水合物的新制备方法及其水系干燥
CN108997198A (zh) 一种盐酸替罗非班的制备方法
CN103282355A (zh) α-氨基-γ-丁内酯的制造方法
CN112694445B (zh) 一种噁拉戈利钠中间体的纯化方法
CN101180263B (zh) 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
EP4434969A1 (en) Anti-sars-cov-2 drug
JP7452881B2 (ja) 心血管疾患の処置に有用な新規化合物
EP4504342B1 (en) Bifunctional peptide with mucoadhesive and virus binding properties
CN105037291A (zh) 一种靛红酸酐衍生物的制备方法
JP2013526577A5 (https=)
CN104877046B (zh) 一种3位取代的苯甲酰基‑β‑环糊精的制备方法
CN107074811B (zh) 改进的埃索美拉唑光学纯化方法
AR127964A1 (es) Sal novedosa de un derivado de 1-sulfonilpirrol, método de preparación de la misma y composición farmacéutica que comprende la misma
JP2023521554A (ja) 抗ウイルス治療
WO2008003637B1 (en) Isolation and use of amine salts of mycophenolic acid
CN106336439B (zh) 一种二丁酰环磷酸腺苷钙的制备方法
WO2023137875A1 (zh) 一种药物组合物及其抗病毒用途
CN104744415A (zh) 一种合成抗流感药物扎那米韦的新方法
CN108640927A (zh) 一种米尔贝肟的制备方法